Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines

M. Hensler, J. Rakova, L. Kasikova, T. Lanickova, J. Pasulka, P. Holicek, M. Hraska, T. Hrnciarova, P. Kadlecova, A. Schoenenberger, K. Sochorova, D. Rozkova, L. Sojka, J. Drozenova, J. Laco, R. Horvath, M. Podrazil, G. Hongyan, T. Brtnicky, MJ....

. 2022 ; 11 (1) : 2101596. [pub] 20220722

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025171

Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and systemic immunosuppression at baseline. An autologous DC-based vaccine (DCVAC) has recently been shown to improve progression-free survival and overall survival in randomized clinical trials enrolling patients with lung cancer (SLU01, NCT02470468) or ovarian carcinoma (SOV01, NCT02107937), but not metastatic castration-resistant prostate cancer (SP005, NCT02111577), despite a good safety profile across all cohorts. We performed biomolecular and cytofluorometric analyses on peripheral blood samples collected prior to immunotherapy from 1000 patients enrolled in these trials, with the objective of identifying immunological biomarkers that may improve the clinical management of DCVAC-treated patients. Gene signatures reflecting adaptive immunity and T cell activation were associated with favorable disease outcomes and responses to DCVAC in patients with prostate and lung cancer, but not ovarian carcinoma. By contrast, the clinical benefits of DCVAC were more pronounced among patients with ovarian carcinoma exhibiting reduced expression of T cell-associated genes, especially those linked to TH2-like signature and immunosuppressive regulatory T (TREG) cells. Clinical responses to DCVAC were accompanied by signs of antitumor immunity in the peripheral blood. Our findings suggest that circulating signatures of antitumor immunity may provide a useful tool for monitoring the potency of autologous DC-based immunotherapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025171
003      
CZ-PrNML
005      
20221031101152.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/2162402X.2022.2101596 $2 doi
035    __
$a (PubMed)35898703
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hensler, Michal $u Sotio Biotech, Prague, Czech Republic
245    10
$a Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines / $c M. Hensler, J. Rakova, L. Kasikova, T. Lanickova, J. Pasulka, P. Holicek, M. Hraska, T. Hrnciarova, P. Kadlecova, A. Schoenenberger, K. Sochorova, D. Rozkova, L. Sojka, J. Drozenova, J. Laco, R. Horvath, M. Podrazil, G. Hongyan, T. Brtnicky, MJ. Halaska, L. Rob, A. Ryska, A. Coosemans, I. Vergote, AD. Garg, D. Cibula, J. Bartunkova, R. Spisek, J. Fucikova
520    9_
$a Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and systemic immunosuppression at baseline. An autologous DC-based vaccine (DCVAC) has recently been shown to improve progression-free survival and overall survival in randomized clinical trials enrolling patients with lung cancer (SLU01, NCT02470468) or ovarian carcinoma (SOV01, NCT02107937), but not metastatic castration-resistant prostate cancer (SP005, NCT02111577), despite a good safety profile across all cohorts. We performed biomolecular and cytofluorometric analyses on peripheral blood samples collected prior to immunotherapy from 1000 patients enrolled in these trials, with the objective of identifying immunological biomarkers that may improve the clinical management of DCVAC-treated patients. Gene signatures reflecting adaptive immunity and T cell activation were associated with favorable disease outcomes and responses to DCVAC in patients with prostate and lung cancer, but not ovarian carcinoma. By contrast, the clinical benefits of DCVAC were more pronounced among patients with ovarian carcinoma exhibiting reduced expression of T cell-associated genes, especially those linked to TH2-like signature and immunosuppressive regulatory T (TREG) cells. Clinical responses to DCVAC were accompanied by signs of antitumor immunity in the peripheral blood. Our findings suggest that circulating signatures of antitumor immunity may provide a useful tool for monitoring the potency of autologous DC-based immunotherapy.
650    12
$a protinádorové vakcíny $x terapeutické užití $7 D019496
650    _2
$a epiteliální ovariální karcinom $x farmakoterapie $7 D000077216
650    _2
$a dendritické buňky $x metabolismus $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x farmakoterapie $x terapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory vaječníků $x genetika $x terapie $7 D010051
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rakova, Jana $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Kasikova, Lenka $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Lanickova, Tereza $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Pasulka, Josef $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Holicek, Peter $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Hraska, Marek $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Hrnciarova, Tereza $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Kadlecova, Pavla $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Schoenenberger, Andreu $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Sochorova, Klara $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Rozkova, Daniela $u Sotio Biotech, Prague, Czech Republic
700    1_
$a Sojka, Ludek $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Drozenova, Jana $u Department of Pathology 3rd Faculty of Medicine, And University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Horvath, Rudolf $u Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Podrazil, Michal $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Hongyan, Guo $u Department of Gynecology and Obstetrics, Peking University Third Hospital, Beijing, Hebei Province, China
700    1_
$a Brtnicky, Tomas $u Department of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
700    1_
$a Halaska, Michal J $u Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Rob, Lukas $u Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Coosemans, An $u Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Belgium
700    1_
$a Vergote, Ignace $u Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Belgium $u Department of Oncology, Leuven Cancer Institute, Laboratory of Gynaecologic Oncology, KU Leuven, Belgium $u Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium
700    1_
$a Garg, Abhishek D $u Laboratory of Cell Stress and Immunity, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
700    1_
$a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Bartunkova, Jirina $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Spisek, Radek $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
700    1_
$a Fucikova, Jitka $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
773    0_
$w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 11, č. 1 (2022), s. 2101596
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35898703 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101148 $b ABA008
999    __
$a ok $b bmc $g 1854730 $s 1176461
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 11 $c 1 $d 2101596 $e 20220722 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace